gene_symbol
HLA-A
hgnc_id
HGNC:4931
binding_type
antigen recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes tumor-specific CD8+ T cells via dendritic cell presentation; activated T cells then kill tumor cells presenting vaccine-derived peptides on HLA-A through TCR recognition and perforin/granzyme-mediated cytolysis. HLA-A itself is not the direct cytotoxic target.
enzyme_product
Off
epitope
On
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Peptide loading for CD8+ T-cell priming
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05846516
disease_id_num_tar_ref
5560
drug_id_num_tar_ref
15137